An Oklahoma man is in full remission after doctors diagnosed a rare autoimmune brain disease following years of unexplained symptoms and misdiagnoses. An estimated 25 to 30 million Americans live with ...

Phase 2 Data Strengthened, Strong Cash Position, and Phase 3 Planning Well Advanced −Highlights Phase 2 data for ATH434 in Multiple System ...

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today issued ...

Acting out dreams linked to later cognitive decline.

After witnessing my father’s tortuous battle with the illness I wanted to understand my own risk, so I visited a brain expert ...

Biogen Inc forecast 2026 profit above Wall Street’s expectations, signalling that steep cost-cutting measures are cushioning ...

ABLi Therapeutics ("ABLi"), a biotechnology company developing therapeutics to address diseases that are associated with activation of Abelson Tyrosine Kinases (c-Abl kinases), announces it has ...

FDA approvals, trial progress and early commercial momentum put several ASX healthcare companies in a strong position heading ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new late-breaking data from the Phase III FENtrepid study showing the investigational Bruton's tyrosine kinase (BTK ...

Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of non-inferiority compared to the current standard of care, OCREVUS, in ...

Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of non-inferiority compared to the current standard of care, OCREVUS, in reduc ...

The thymus peptide upregulated 1,198 genes tied to energy metabolism, DNA repair, and cell cycle regulation. The Thymus ...